TP53 and in situ carcinoma: CIS, a well-characterized DNA crosslinking agent, is known to activate the G1/S checkpoint through p53-dependent and p53-independent pathways in response to DNA damage, thereby halting cell cycle progression to allow for repair or trigger apoptosis (Siddik, 2003; Kelland, 2007).